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Abstract
Background: There remains debate about the screening strategies for albuminuria. This study evaluated whether a
screening strategy in an apparently healthy population based on basic clinical and biochemical parameters could be more
effective than a strategy where screening for albuminuria is performed unselectively.
Methodology/Principal Findings: The Unreferred Renal Insufficiency (URI) Study is a cross-sectional study on the
prevalence of metabolic risk factors in Belgian workers, volunteering to be screened during a routine yearly occupational
check-up. Subjects (n = 295) with treated hypertension, known diabetes, treated dyslipidaemia, cardiovascular and renal
disease were excluded. Among 1,191 apparently healthy subjects, 23% had unknown hypertension, 13% had impaired
glucose tolerance, 15.4% had normoalbuminuria, 4.2% had microalbuminuria and 0.4% had macroalbuminuria. Subjects
with resting heart rate $85 bpm, plasma glucose $5.6 mmol/L and blood pressure $140/90 mmHg were associated with
albuminuria of any degree. A strategy where only subjects with at least one of these risk factors (n = 431) were screened for
albuminuria, would identify all subjects with macroalbuminuria (5/5), 64% of those with microalbuminuria (32/50), and less
than half of those with normoalbuminuria (81/183). An alternative strategy whereby subjects were first screened for
presence of albuminuria, and additional cardiovascular risk factors were only measured in subjects positive for albuminuria
(n = 238), would identify only 27% (118/431) of the subjects with additional and potentially modifiable cardiovascular risk
factors. On the other hand, half of the subjects in this study with albuminuria (120/238, of which 102 had
normoalbuminuria), had no additional cardiovascular risk factor at all.
Conclusions: Screening an apparently healthy population directly for albuminuria will result in a high percentage of false
positives, mostly measured in the normal range. Screening for microalbuminuria and macroalbuminuria based on presence
of additional, potentially modifiable risk factors appears to be more beneficial. Trial registration 2006 NCT00365911
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Introduction
The number of patients with end stage renal disease (ESRD) in
need of renal replacement therapy has dramatically increased over
the last decades [1]. A substantial part of this increase is
attributable to the rising prevalence of diabetes and/or hyperten-
sion [2,3,4]. Microalbuminuria seems to be an important predictor
of progressive renal disease and end stage renal disease in diabetic
and hypertensive subjects [5,6]. It has been demonstrated that in
these populations, preventive measures can delay the evolution to
macroalbuminuria and potentially also the progression to renal
failure [7,8]. Consequently, it is advised to screen these high risk
subjects with diabetes and hypertension, in order to identify and
eventually treat those at risk for progressive renal disease.
Extending this line of reasoning, some authors advocate to screen
also low risk groups, or even the general population, arguing that
most persons with albuminuria and/or reduced eGFR (,60 ml/
min/1.73 m2) are asymptomatic [9]. Van der Velde et al e.g.
found that 45% of subjects with microalbuminuria were younger
than 55 years and had no hypertension or diabetes [9]. It is
debated whether such a large scale screening project should be
advocated [10,11]. Concerns are not only the cost of screening
itself, but more importantly, the risk and the cost of treating false
positive subjects [12]. In the study by van der Velde et al, out of
40,854 subjects screened, 7.8% (n= 3,200) had at least microal-
buminuria, but only 45 of those developed ESRD over a 9 year
follow up period [9]. In addition, effective screening presumes that
an intervention to alter the course of the disease is available [13],
which is not the case if the subject only has albuminuria and no
other modifiable risk factor. It would therefore be very useful to
develop a screening strategy based on additional, modifiable, risk
factors to enhance the yield of screening without having too much
false positives, and to make interventions possible.
In this study, we used data collected in an apparently healthy
working population, aged 17 to 65 years, to evaluate which easily
obtainable parameters or combinations of them are associated
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with albuminuria, and whether using these risk factors can be of
help to increase the effectiveness of a screening program.
Methods
Objectives
The primary aim was to determine the prevalence of different
levels of albuminuria, some (cardiovascular) risk factors and their
associations, to develop a rational screening strategy for albumin-
uria in the healthy population.
Participants
The Unreferred Renal Insufficiency (URI) is a cross sectional
study that included only Caucasian workers (n = 1,486) who
presented at a routine yearly occupational check-up between
January 2007 and December 2009, in Belgium. The presence of
more than 100 leukocytes/ml (2.2%), and/or more than 50
erythrocytes/ml (2.4%) in the urinary sediment were considered as
confounders for reliable measurement of urinary albumin; these
subjects and subjects with incomplete data (1.8%) were conse-
quently excluded from further analysis. Subjects with known
comorbid conditions or risk factors of which it is well established
that they could affect albuminuria, such as diabetes (1.2%),
cardiovascular disease (0.3%), renal disease (0.4%), subjects on
antihypertensive drugs (8.3%) and on lipid lowering drugs (3.3%)
were also excluded, leaving a cohort of 1,191 apparently healthy
subjects for analysis.
Description of procedures
All subjects were investigated during their yearly check up by
their occupational physician. Body weight was recorded to the
nearest 0.1 kg and height was measured to the nearest centimeter.
Waist circumference was measured by trained nurses following
recommendations by WHO [14]. Body mass index (BMI) was
calculated as body weight in kg divided by height2 (kg/m2). Blood
pressure and resting heart rate were measured in sitting position by
a calibrated electronic device (OMRONH). A questionnaire about
current cigarette smoking, physical activity and prescribed medica-
tion was taken by an occupational physician in each participant. A
random blood and urine spot specimen was collected and analyzed
on the same day in one central laboratory (no frozen samples).
Urinary albumin was measured by an immune turbidimetric
method with an inter-assay coefficient of variation of 11.2% at a
mean level of 82 g/L and an inter-assay coefficient of variation of
4.9% at a mean level of 580 g/l. Serum creatinine was analyzed by
a colorimetric assay (compensated Jaffe reaction), calibrated by
Isotope Dilution Mass Spectrometry (IDMS), with an inter-assay
coefficient of variation of 1.75% at a mean level of 104 mmol/l mg/
dl (Roche). Serum CRP was measured with an immune
turbidimetric method with an inter-assay coefficient of variation
of 4.6% at a mean level of 3.2 mg/l and inter-assay coefficient of
variation of 2.5% at a mean level of 5.5 mg/l.
Definitions
Gender specific urinary albumin creatinine ratio (uACR) cutoff
values as proposed by Warram et al. were used because men have
a higher urinary excretion of creatinine than women due to higher
muscle mass. Normoalbuminuria was defined as uACR: 0.6–
1.8 mg/mmol (5–16 mg/g) in men and uACR 0.8–2.7 mg/mmol
(7–24 mg/g) in women, microalbuminuria was defined as uACR
1.9–27 mg/mmol (17–249 mg/g) in men and uACR 2.8–39 mg/
mmol (25–354 mg/g) in women, macroalbuminuria was defined
as uACR $28 mg/mmol (250 mg/g) in men and uACR
$40 mg/mmol (355 mg/g) in women [15]. The Modification of
Diet in Renal disease (MDRD) equation was used to assess the
estimated GFR: eGFR=30849 6 standardized Scr
21.154 6
age20.203 6 1.212 [if black] 6 0.742 [if female] [16]. Impaired
glucose tolerance (IGT) was defined as a plasma glucose level
$5.6 mmol/L [17]. Hypertension was defined as diastolic
blood pressure $90 mmHg and/or systolic blood pressure
$140 mmHg. Obesity was defined as BMI .30 kg/m2. Abdom-
inal adiposity was defined according the National Cholesterol
Education Program (NCEP) criteria: waist circumference .102 in
men and.88 cm in women. Hypercholesterolemia was defined as
serum total cholesterol .6.5 mmol/L.
Ethics
A written informed consent was obtained from all participants.
The Ethics Committee of University Hospital Ghent approved the
study (2006-038).
Statistical methods
SPSS 15.0 was used for all calculations. Results are presented as
percentages or as mean 6 standard deviation. The baseline
characteristics of groups were compared by use of ANOVA: post-
hoc Scheffe´ test (continuous variables), Kruskal-Wallis (continuous
variable with a skewed distribution) and a Chi-square test
(categorical variables). Ordinal regression analysis was performed
to select the associated risk factors with different categories of
albuminuria, in a random selection of 50% of the subjects. The
significant continuous variables were dichotomized. These risk
factors were validated in the other 50% of the sample. The
prevalence and test characteristics, of normo-, micro- and
macroalbuminuria were calculated, if at least one of these risk
factors was present. The sensitivity was defined as the number of
subjects with true-positive test results divided by the total number
of subjects with albuminuria. The specificity was defined as the
number of true-negative test results divided by the total of number
of subjects without albuminuria. The positive predictive value was
defined as the number of true-positive test results divided by the
total number of positive test results. The negative predictive value
was defined as the number of true negative test results divided by
the total number of negative test results. The positive likelihood
ratio was defined as sensitivity divided by 1-specificity; the negative
likelihood ratio was defined as 1-sensitivity divided by specificity.
Results
Our cohort (n = 1,191) of apparently healthy subjects, after
excluding those with treated hypertension, treated dyslipidaemia,
known diabetes, cardiovascular or renal disease, still had a high
prevalence of unknown hypertension, dyslipidaemia and impaired
glucose metabolism.
Table 1 shows the basic characteristics and cardiovascular risk
factors of the cohort.
Almost all subjects (98.9%) had an estimated GFR higher than
60 ml/min/1.73 m2 and none had an estimated GFR lower than
50 ml/min/1.73 m2. As expected, the cohort was rather young
(age 38.369.7 years, range 17–64). Albumin was detected in the
urine of one fifth. The large majority of albuminuric subjects had
normoalbuminuria, fewer subjects had microalbuminuria and
macroalbuminuria was only rarely observed (table 1). Table 2
shows the distribution of some measured clinical and biochemical
parameters in subgroups according to different levels of albumin-
uria. In a randomly selected cohort (n = 599), a multivariate
ordinal regression model selected resting heart rate, plasma
glucose and hypertension as significant independent predictors
for presence of albuminuria at any degree (table 3). The
Screening for Albuminuria
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continuous variables were dichotomized (0 or 1) as follows: resting
heart rate $85 bpm (cutoff level according to the 90th percentile);
plasma glucose: $5.6 mmol/L (impaired glucose tolerance).
Consequently, the prevalence of normoalbuminuria, microalbu-
minuria and macroalbuminuria in this randomly selected cohort,
was higher in subjects with at least one risk factor (n = 206) than in
subjects with no risk factors (n = 393), respectively: 21.4 vs 14.1%
(n= 44 vs 58); 8.7 vs 3.1% (n= 18 vs 12) and 1.5 vs 0% (n= 3 vs 0),
p,0.001. Our risk assessment was validated in the other randomly
selected cohort (n = 592). The prevalence of normoalbuminuria,
microalbuminuria and macroalbuminuria in this validation
cohort, was also higher in subjects with at least one risk factor
(n = 225) than in subjects with no risk factors (n = 367),
respectively: 16.4 vs 12% (n= 37 vs 44); 6.2 vs 1.6% (n= 14 vs
6) and 0.9 vs 0% (n= 2 vs 0), p = 0.001. Table 4 shows the test
characteristics for subjects with at least one risk factor, to identify
normoalbuminuria, microalbuminuria and macroalbuminuria in
both randomly selected cohorts. Because our risk assessment fitted
quite well in both cohorts, we applied it in the complete
population. The prevalence of normoalbuminuria, microalbumin-
uria and macroalbuminuria in the complete population, was
higher in subjects with at least one risk factor (n = 431) than in
subjects with no risk factors (n = 760), respectively; 18.8 vs 13.4%
(n= 81 vs 102); 7.4 vs 2.4% (n= 32 vs 18) and 1.2 vs 0% (n= 5 vs
0), p,0.001 (figure 1).
We evaluated two strategies for screening albuminuria in our
population, one strategy where a set of additional risk factors were
screened as first line, with later screening for albuminuria only in
subjects with at least one of those additional risk factors and an
alternative strategy where albuminuria was screened as first line, and
additional risk factors were measured only in those with albuminuria.
A strategy where only subjects with at least one modifiable risk
factor (n = 431) were screened for albuminuria, would identify all
subjects with macroalbuminuria (5/5), 64% of subjects with
microalbuminuria (32/50), but less than half of those with
normoalbuminuria (81/183), table 4 shows the corresponding
likelihoods and predictive values.
An alternative strategy whereby subjects were first screened for
presence of albuminuria, and additional cardiovascular risk factors
were only measured in subjects positive for albuminuria (n = 238),
would identify only 27% (118/431) of the subjects with additional
and potentially modifiable cardiovascular risk factors. On the
other hand, half of the subjects in this study with albuminuria
(120/238, of which 102 had normal range albuminuria), had no
additional cardiovascular risk factor at all.
Table 5 shows that subjects with no modifiable risk factor had
also lower levels of risk factors which were not included in our
screening model.
Table 1. Basic characteristics and metabolic risk factors of
1,191 apparently healthy subjects.
Parameters N %
Male gender 998 83.8
Unknown hypertension 279 23.4
Unknown hypercholesterolemia 86 7.2
Unknown IGT/diabetes 150 13.3
Obesity (BMI.30 kg/m2) 160 13.5
Abdominal adiposity (%) 168 16.0
No physical activity 491 49.2
Current smoking 370 32.4
Normoalbuminuria 183 15.4
Microalbuminuria 50 4.2
Macroalbuminuria 5 0.4
Unknown impaired glucose tolerance (IGT)/diabetes: plasma glucose
$5.6 mmol/L. Hypercholesterolemia: serum cholesterol .6.5 mmol/L.
Hypertension: RR $140 and/or 90 mmHg.
doi:10.1371/journal.pone.0013328.t001
Table 2. Metabolic risk factors in subjects with different level
of albuminuria.
Albuminuria no Normo- Micro- Macro-
n= 1,191 (%) 953 183 (15.4) 50 (4.2) 5 (0.4)
Age (years) 38.269.6 38.7610.1 38.8610.7 39.069.1
Men (%) 799 (83.8) 147 (80.3) 47 (94) 5 (100)
Systolic blood
pressure (mmHg)
126.9613.8 129.8614.1 132.6618.3* 142.6611.2
Diastolic blood
pressure (mmHg)
77.469.9 79.9610.6* 80.8613.2 9068.9*
Unknown hyper-
tension
199 (20.9) 55(30.1)* 20 (40)** 5(100)**
Resting heart rate 69.5610.3 72.6611.3** 75.9616.1** 78.863.7
Total cholesterol
(mmol/L)
5.061.0 5.161.0 4.961.1 7.061.0**
Plasma glucose
(mmol/L)
4.860.7 5.061.2* 5.060.9 5.261.1
Unknown IGT/
diabetes (%)
103 (11.5) 34(19.3)* 12(24)* 1(20)
Body mass index
(kg/m2)
25.963.9 25.564.3 25.365.3 27.562.7
Abdominal
adiposity (%)
135(16.1) 21 (12.7) 11(25.6) 1 (25)
Serum uric acid
(mmol/L)
315671 315677 339677 4826119**
White blood cell
count (109/L)
7.061.9 7.261.9 7.962.3** 8.061.8
C-reactive protein
(mg/L)
2.264.8 2.564.2 4.161.0 3.463.6
Current smoking
(%)
283(31) 64 (35.6) 20 (40) 3 (60)
Unknown impaired glucose tolerance (IGT)/diabetes: plasma glucose
$5.6 mmol/L.
Hypertension: RR $140 and/or 90 mmHg. *p,0.05, **p,0.01 versus no
albuminuria.
doi:10.1371/journal.pone.0013328.t002
Table 3. Multivariate regression analyses to predict different
categories of albuminuria.
Random sample n=599, R2 = 0.07 E St error P
Resting heart rate (beats per min) 0.026 0.009 0.006
Plasma glucose (mmol/L) 0.341 0.141 0.015
Unknown Hypertension 0.487 0.237 0.040
White blood cell count 0.079 0.053 0.132
Serum uric acid (mmol/L) 0.001 0.001 0.464
Total serum cholesterol (mmol/L) 20.106 0.104 0.310
doi:10.1371/journal.pone.0013328.t003
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Discussion
Our data indicate that albuminuria, unknown hypertension and
impaired glucose metabolism are quite prevalent findings in an
apparently healthy population. When present, albuminuria was
mostly measured in the normal range, and was frequently found in
subjects without other modifiable risk factors, making its relevance
as a predictor of outcome questionable. A screening strategy for
albuminuria starting from assessment of simple and easy to obtain
risk factors, such as resting heart rate, blood pressure and plasma
glucose level identified subjects at risk for micro- and macroalbu-
minuria in a more effective way than a strategy of screening a
healthy population for albuminuria alone.
There is little debate that screening for albuminuria should be
performed in patients with diabetes and/or hypertension, where early
intervention can slow down deterioration of renal function. Whether
it should also be performed in the general population remains
ambigiuous [12,18,19]. There is heated debate whether screening the
healthy population for presence of albuminuria is fulfilling all
conditions requested to define a successful screening program [13].
A first request is that the screened factor either relates to an
important health risk, or is prevalent in the population. In our
healthy population, the prevalence of albuminuria was 20%.
However, many cases had normoalbuminuria without additional
risk factors. Those in favor of screening the general population
argue that an urinary albumin excretion .5 mg/min is related
with increased risk of cardiovascular morbidity and mortality
[20,21,22]. In some of these studies, an adjustment for presence of
hypertension and diabetes was performed, indicating that
albuminuria is an independent risk factor on top of diabetes and
hypertension, but it is not clear whether the increased risk was also
present in those with normal blood pressure and glucose levels
[21]. In the PREVEND cohort, hypertension and diabetes were
not actually assessed objectively, but were based on ‘‘self declared’’
status [23]. In our study, the prevalence of unknown hypertension
and impaired glucose levels was high, even after excluding subjects
Table 4. Test characteristics to identify normo-, micro- and macroalbuminuria with at least one risk factor in randomly selected
populations and in the complete ‘‘healthy’’ population.
Population albuminuria sensitivity specificity PPV NPV LR+ LR2
random cohort n = 599 Normo- 43 70 24 85 1.4 0.8
Micro- 60 70 11 96 2.0 0.6
Macro- 100 70 2 100 3.3 <0
validation cohort n = 592 Normo- 46 65 18 88 1.3 0.8
Micro- 70 65 8 98 2.0 0.5
Macro- 100 65 1 100 2.9 <0
complete population n= 1191 Normo- 44 67 21 86 1.3 0.8
Micro- 64 67 9 97 1.9 0.6
Macro- 100 67 1 100 3.0 <0
PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood and LR2: negative likelihood ratio.
doi:10.1371/journal.pone.0013328.t004
Figure 1. The prevalence of albuminuria in subjects with at
least one vs. none risk factors.
doi:10.1371/journal.pone.0013328.g001
Table 5. Cardiometabolic profile in subjects with none versus
one or more risk factors.
Risk factors None $1 p
N 760 431
Age 37.069.4 40.669.8 ,0.001
Male gender (%) 604 (79.5) 394 (91.48) ,0.001
Resting heart rate (bpm) 67.768.3 74.9613.1 ,0.001
Systolic blood pressure
(mmHg)
121.9610.4 137.9614.1 ,0.001
Diastolic blood pressure
(mmHg)
74.468.3 84.3610.2 ,0.001
Plasma glucose (mmol/L) 4.660.5 5.361.0 ,0.001
White blood cell count
(10*109/L)
6.961.9 7.361.9 ,0.001
Body mass index (kg2/m) 25.263.6 26.964.4 ,0.001
Abdominal obesity (%) 72 (10.8) 96 (24.8) ,0.001
Obesity .30 kg/m2 (%) 71 (9.4) 89 (20.6) ,0.001
Total cholesterol (mmol/L) 4.960.9 5.361.0 ,0.001
Serum uric acid (mmol/L) 305670 336677 ,0.001
C-reactive protein (mg/L) 2.063.4 3.067.0 ,0.001
Current smoking 225 (30.7) 145 (34.9) 0.130
No physical activity 282 (44.3) 209 (57.9) ,0.001
doi:10.1371/journal.pone.0013328.t005
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with known risk factors, so most likely also in the PREVEND
cohort a substantial part of ‘‘false negatives’’ for hypertension and
impaired glucose tolerance are present. Accordingly, the definition
of ‘‘healthy population’’ in the PREVEND cohort is probably not
correct, making also the recommendation to screen the healthy
population incorrect, as most likely a substantial number of
subjects in this ‘‘healthy cohort’’ would have hypertension or
elevated glucose levels if these would have been measured. In
other studies restricted to non-diabetic and non-hypertensive
subjects, although the increased risk for renal disease in those with
microalbuminuria seems dramatic, the absolute risk remains low,
with less than 0.1% of persons with microalbuminuria ending up
on renal replacement therapy, or 0.6% developing cardiovascular
disease over an 8 year period [9,24]. In the PREVEND study, the
relation between albuminuria and decline of renal function in
subjects without known risk factors, was only observed in those
individuals with macroalbuminuria [9]. As mentioned, in our
study, all subjects with macroalbuminuria would be detected if
only subjects with more than one risk factor were screened, as
none of the subjects without risk factors (the truly healthy
population) had macroalbuminuria. In our cohort, the prevalence
of microalbuminuria, in subjects without risk factors, was 2.4%. A
similar figure was found in a New Zealand study (2.0%) in subjects
without diabetes, impaired glucose tolerance, hypertension or
dyslipidaemia [25]. In the Copenhagen City Heart Study, the
prevalence of microalbuminuria was also 2.0% in subjects without
any feature of the metabolic syndrome, and these subjects had no
increased risk for cardiovascular disease and death, suggesting that
microalbuminuria by itself might not be an independent
determinant of outcome without presence of associated risk factors
[26]. It can be that this microalbuminuria is the equivalent of
‘‘exertional’’ [27] or ‘‘orthostatic’’ albuminuria.
Another request for a screening program to be meaningful and
effective, is that risk factors should be modifiable. As a prospective
trial to test the hypothesis that medical management of microalbu-
minuria affects patient-centered events independent of blood
pressure reduction is still lacking [28], screening for microalbumin-
uria in subjects without measured additional risk factors, appears
not to be justified from a general health care perspective.
In our cohort of apparently healthy subjects, the likelihood of
having albuminuria was related to the well established and
potentially modifiable risk factors blood pressure and plasma
glucose level, but also to resting heart rate. Two thirds of our
cohort had none of these risk factors. Table 5 shows that those
subjects had also much lower levels of other cardiovascular risk
factors not included in our risk score. Nevertheless, 13.4% of these
subjects had normoalbuminuria, but none had macroalbuminuria.
Most likely, these subjects have thus a very low absolute risk for
cardiovascular or renal disease, and the potential benefit of a
treatment should be considered very low. Consequently, a strategy
of screening only in those with at least one risk factor would miss
only few potentially relevant cases, at the same time avoiding
many ‘‘false positives’’, who compose nearly 50% of albuminuric
subjects when unrestricted screening for albuminuria is performed
first. However, testing for albuminuria in subjects with additional
cardiovascular risk factors is warranted, as a more aggressive
treatment can be defended in subjects with additional risk factors
in presence of albuminuria compared to those with risk factors but
without albuminuria.
There is substantial evidence that reduction of blood pressure,
decreases the progression of renal disease and reduces cardiovascular
events [29,30,31]. Disturbed glucose metabolism, as indicated by
increased plasma glucose levels, is a condition with increased risk for
the development of overt diabetes. Life style modification, and the use
of drugs such as metformin and acarbose can slow down progression
to overt diabetes and/or cardiovascular disease in these subjects [32].
The association of resting heart rate with albuminuria was previously
mentioned [33,34]. An explanation could be that a high resting heart
rate may cause mechanical stress that might contribute to renal
endothelial dysfunction leading to albuminuria [35]. Previous reports
mentioned that tachycardia as a sign of sympathetic overactivity, is an
independent risk factor for chronic kidney disease, cardiovascular and
noncardiovascular mortality, even in an apparently healthy popula-
tion [34,36,37,38]. Reduction of sympathetic overactivity by regular
physical activity and smoking cessation appear to be beneficial in this
patient group [39]. Carvedilol appears to reduce proteinuria to a
higher degree than expected by the blood pressure lowering effect
alone in patients with hypertension, but it is unclear whether this
effect is due to the reduction in heart rate modification or to genuine
metabolic effects [40].
A strength of this study is the nearly 100% participation rate of
a relatively young and apparently healthy occupational popula-
tion. A limitation is that we only measured urinary albumin to
creatinine ratio at one occasion, guidelines recommend to have at
least two positive albumin to creatinine ratio’s in three consecutive
first morning urine samples before labeling a person with
microalbuminuria [41]. Furthermore, the prevalence of microal-
buminuria was underestimated if albumin to creatinine ratio was
measured in morning urine samples [42], while an overestimation
was observed if random samples were obtained [43]. Thus, the
association between subjects with albuminuria and additional risk
factors could be confounded by measuring the urinary albumin to
creatinine ratio at only one random occasion.
In conclusion, our data provide evidence to support the concept
that screening for albuminuria should only be performed in
subjects with additional and potentially modifiable risk factors, and
that this strategy is more beneficial than screening the general
population. We identified 3 parameters that are easy and cheap to
obtain: blood pressure, plasma glucose and resting heart rate to
identify subjects in whom further assessment of presence of
albuminuria might be relevant.
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